
Faye Johnson MD PhD, 2026 ENA Targets: Antibody-Drug Conjugate MICVO Targets Extracellular Matrix to Treat Metastatic Head & Neck Cancers After Platinum or Immunotherapy
Faye Johnson
BARCELONA, Spain—Patients with metastatic head and neck cancers that recurred despite platinum based chemotherapy or immunotherapy had significant responses to treatment with the antibody-drug conjugate micvotabart pelidotin as monotherapy in a phase one study reported at the 2026 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. Peter Goodwin heard the latest from the study’s lead author Faye Johnson MD PhD, Professor of Thoracic/Head & Neck Medical Oncology at the MD Anderson Cancer Center in Houston, USA
Antibody-Drug Conjugate MICVO Targets Extracellular Matrix to Treat Metastatic Head & Neck Cancers After Platinum or Immunotherapy
An interview with:
Faye Johnson MD PhD, Professor of Thoracic/Head & Neck Medical Oncology, MD Anderson Cancer Center, Houston, USA
BARCELONA, Spain—Patients with metastatic head and neck cancers that recurred despite platinum based chemotherapy or immunotherapy had significant responses to treatment with the antibody-drug conjugate micvotabart pelidotin as monotherapy in a phase one study reported at the 2026 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.
Peter Goodwin heard the latest from the study’s lead author Faye Johnson MD PhD, Professor of Thoracic/Head & Neck Medical Oncology at the MD Anderson Cancer Center in Houston, USA
AUDIO JOURNAL OF ONCOLOGY: Faye Johnson MD PhD
Source:
ENA 2026 Molecular Targets and Cancer Therapeutics Symposium
Abstract no: 3LBA :
Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
F. Johnson1, T.J. Roberts2, W. Wong3, D. Castellano Gauna4, D.J. Wong5, N.F. Saba6, T.M. Wise-Draper7, J.P. Machiels8, J.C. Park9, A. Spira10, E. Calvo11, D. Roda Perez12, H. Wang13, A. Elfiky13, X. Qing13, O. Bogg13, S. He13, S. Lewandowski13, A.L. Ho14
1University of Texas- MD Anderson Cancer Center, Department of Thoracic-Head & Neck Med Oncology, Houston, USA
2Mass General Brigham Cancer Institute, Center for Head and Neck Cancers, Boston, USA
3Memorial Sloan Kettering Cancer Center, MSK’s Division of Solid Tumor Oncology, New York, USA
4Hospital Universitario 12 de Octubre Madrid, Department of Medicine, Madrid, Spain
5Ronald Reagan UCLA Medical Center, Department of Medicine, Los Angeles, USA
6Emory University, Department of Hematology and Medical Oncology, Atlanta, USA
7University of Cincinnati, Department of Internal Medicine- Hematology and Oncolog, Ohio, USA
8Cliniques universitaires Saint-Luc, Department of Medical Oncology, Brussels, Belgium
9Dana Farber Cancer Institute, Medical Oncology, Boston, USA
10NEXT Oncology Virgina, Medical Oncology, Fairfax, USA
11START-CIOCC Madrid, Medical Oncology, Madrid, Spain
12Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain
13Pyxis Oncology, Clinical Development, Boston, USA
14Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, USA
Background:
R/M HNSCC post-platinum and anti-PD-1 therapy lacks standard of care treatment options and remains a high unmet need. MICVO is a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural protein in the tumor extracellular matrix, comprising an IgG1 monoclonal antibody with site-specific conjugation to a protease-cleavable linker and optimized auristatin payload.
Methods:
MICVO was given intravenously at 5.4 mg/kg Q3W to patients (pts) with R/M HNSCC who progressed on platinum and anti-PD-(L)1. Dose was capped at 432 mg (male ≥ 80 kg) or 378 mg (female ≥ 70 kg) during dose expansion. We report results for 35 pts whose first dose was ≤ the cap; 33/35 were efficacy evaluable. Endpoints include objective response rate (ORR) by investigator (RECIST v1.1), progression-free survival (PFS), overall survival (OS), and safety. (NCT05720117).
Results:
As of 18Aug2026, among 35 pts, 51% had HPV-positive oropharyngeal cancer (OPC). 69% (24) pts had ≥ 2 prior lines of therapy for R/M disease (median 2, range 1–4). 71% had prior taxane. 57% had prior anti-EGFR agents. Confirmed ORR was 36% (12/33, including one complete response). Disease control rate was 94% (31/33). Median PFS was 6.2 months (mos) (95% CI 4.8, 8.8).12-mos OS probability was 79% (95%CI 58%, 90%). Median OS was not reached (NR) (95%CI NR, NR). Clinical benefit was observed across HPV status and prior treatment subgroups (Table 1). Among 12 confirmed responders, 75% (9) achieved response by week 6, and 83% (10) had > 50% tumor reduction from baseline.
Efficacy Evaluable
ORR, %(n)
mPFS, mos
HPV Status
HPV+ OPC (N=17)
HPV-unrelated (N=16)
35% (6)
38% (6)
6.2
5.9
Prior anti-EGFR
Yes (N=18)
No (N=15)
28% (5)
47% (7)
5.0
8.8
Prior novel anti-EGFR (bispecific Abs) (N=5)
40% (2)
5.8
Prior Taxane
Yes (N=23)
No (N=10)
35% (8)
40% (4)
6.2
4.9
Line of MICVO Therapy
2L (N=11)
3L (N=20)
4L (N=0)
5L (N=2)
45% (5)
35% (7)
NA
0% (0)
6.7
6.2
NA
Not reported*
*N=2 (actual PFS 5.0, 7.0)
Grade (Gr) ≥3 treatment-related adverse events (TRAEs) reported in ≥ 2 pts (5%) included peripheral sensory (8.6%) and motor (8.6%) neuropathy, AST increased (5.7%), GGT increased (5.7%), hyponatremia (5.7%), lymphocyte count decreased (5.7%), and neutrophil count decreased (5.7%). There was no death due to TRAE. Median time of onset for Gr3 peripheral neuropathy (PN, N=6) was 5.5 mos with 5/6 resolved/improving following dose modification. In pts with Gr3 PN, ORR was 67% (4/6) and mPFS was 8.8 mo. There was no correlation between EDB+FN expression and clinical activity.
Conclusion:
MICVO addresses an unmet need in 2L+ HNSCC and demonstrates promising HPV-agnostic activity including post anti-EGFR with a manageable safety profile with dose capping. The data supports advancing MICVO monotherapy into a pivotal program in 2L+ HNSCC.
Faye Johnson MD PhD A J Oncology Text
November 20, 2026
More from ENA 2026
All 1 interviewsThis is the last of the 1 ENA 2026 interviews. See them all.